Clopidogrel Bisulfate Tablet
Product Images NDC 64980-713

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Clopidogrel Bisulfate (NDC 64980-713). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rising Pharma Holdings, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (Fa68c953 569a 4b02 B423 E33fde91cb4d 01)

Chemical structure diagram of clopidogrel bisulfate showing its molecular composition, including a bicyclic ring, a thienopyridine ring, a chlorine-substituted phenyl group, and a sulfate group (H2SO4).*

FDA Label Image

Image (Fa68c953 569a 4b02 B423 E33fde91cb4d 02)

A horizontal error bar chart illustrating the effect of co-administered proton pump inhibitors (PPIs) on the active metabolite AUC of clopidogrel bisulfate. The chart compares the effect of Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg on the relative change of clopidogrel's active metabolite exposure versus clopidogrel administered alone, with mean values and 90% confidence intervals shown.*

FDA Label Image

Image (Fa68c953 569a 4b02 B423 E33fde91cb4d 03)

This line graph compares the cumulative event rate (%) of cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up between two groups: one receiving placebo with aspirin and the other receiving clopidogrel bisulfate with aspirin. The clopidogrel group shows a consistently lower event rate, with a p-value of 0.00009 indicating statistical significance.*

FDA Label Image

Image (Fa68c953 569a 4b02 B423 E33fde91cb4d 04)

A hazard ratio forest plot comparing Clopidogrel and placebo across subgroups including age, gender, race, elevated cardiac enzymes, diabetes, previous myocardial infarction, and previous stroke. Each subgroup shows the number of patients, event counts, and the hazard ratio with 95% confidence intervals, indicating the relative effect of Clopidogrel versus placebo in these categories.*

FDA Label Image

Iamge (Fa68c953 569a 4b02 B423 E33fde91cb4d 05)

A forest plot chart displaying hazard ratios comparing Clopidogrel Bisulfate and placebo across subgroups based on Heparin/LMWH use, Aspirin dosage, GP IIb/IIIa antagonist use, Beta-blocker use, and Ace inhibitor use. The chart includes patient counts, event percentages for Clopidogrel and placebo groups, and favors either treatment along the hazard ratio scale with 95% confidence intervals.*

FDA Label Image

Image (Fa68c953 569a 4b02 B423 E33fde91cb4d 06)

A line chart comparing the percentage of deaths before first discharge over 28 days since randomization between Clopidogrel and placebo groups. The graph shows Clopidogrel with 1726 deaths (7.5%) and placebo with 1845 deaths (8.1%), indicating a 7% proportional risk reduction (p = 0.03). The y-axis represents percent dead before discharge, and the x-axis shows days since randomization up to 28 days.*

FDA Label Image

Image (Fa68c953 569a 4b02 B423 E33fde91cb4d 07)

A Kaplan-Meier curve graph showing the percentage of patients with death, re-infarction, or stroke before discharge over 28 days since randomization. The graph compares two groups: one receiving clopidogrel and one placebo, indicating event rates and a noted 9% proportional risk reduction with clopidogrel (p = 0.002).*

FDA Label Image

Image (Fa68c953 569a 4b02 B423 E33fde91cb4d 08)

A forest plot illustrating odds ratios with 99% confidence intervals for Clopidogrel versus Placebo across various subgroups, including gender, age at entry, hours since onset, systolic blood pressure categories, heart rate ranges, and fibrinolytic agent use. The chart compares the percentage of patients in each subgroup favoring Clopidogrel or Placebo, with an overall summary at the bottom.*

FDA Label Image

Image (Fa68c953 569a 4b02 B423 E33fde91cb4d 09)

A line graph showing cumulative event rates (%) of fatal or non-fatal vascular events over 36 months of follow-up. Two lines compare aspirin and clopidogrel, with cumulative rates rising over time, and the p-value noted as 0.045, indicating statistical comparison between treatments.*

FDA Label Image

Image (Fa68c953 569a 4b02 B423 E33fde91cb4d 10)

A forest plot chart comparing the hazard ratios with 95% confidence intervals between Clopidogrel and Aspirin across qualifying conditions: Stroke, MI (myocardial infarction), PAD (peripheral artery disease), and overall. The chart displays numerical data for patient counts and event rates for both drugs, visually indicating which treatment is favored per condition.*

FDA Label Image

75mg (Fa68c953 569a 4b02 B423 E33fde91cb4d 11)

Clopidogrel Tablets, USP 75 mg oral tablets packaging label by Rising Pharmaceuticals. The carton indicates a 30 tablet count. The label includes storage instructions, manufacturer Graviti Pharmaceuticals Pvt. Ltd. in India, and distributor Rising Pharma Holdings, Inc. in New Jersey. It notes the product is prescription only and provides a website link for the Medication Guide.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.